logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics raises US$45mln from American investors to advance its gene silencing platform drugs

The private placement of new shares was oversubscribed

Silence Therapeutics PLC -

Silence Therapeutics PLC (LON:SLN) (NASDAQ:SLN) has said it is set to receive US$45mln from an oversubscribed private placement of stock with US investors that will fund the development of its drug pipeline.

In total, 2.02mln American depositary shares were sold for US$22.50 each.

"This financing marks an important step in our journey to increase awareness of Silence and position our company as a global RNAi leader," said Silence chief executive Mark Rothera in a statement.

Silence is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference.

RNAi inhibits the expression of specific target genes thought to play a role in diseases with significant unmet medical need.

Its messenger RNAi GOLD platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver.

It has two drug candidates - SLN360, which is designed to reduce cardiovascular risk in people born with high levels of lipoprotein(a); and SLN124, which is being developed to tackle iron loading anaemias.

The first clinical data from the GOLD platform are due out the first half, followed by patient data from SLN360 and SLN124.

Quick facts: Silence Therapeutics PLC

Price: 568 GBX

AIM:SLN
Market: AIM
Market Cap: £507.79 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: FTSE 100 retreats as UK employment tumbles

Headlines from the Proactive UK newsroom. The FTSE100 was on the back foot as the new job numbers highlighted how business is suffering due to the pandemic. The blue chip-index shed 60 to 6,232. People on UK payrolls fell by 649,000 between March and June, according to the government....

on 16/7/20

2 min read